<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2025.641</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-2514</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАУЧНЫЕ ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Extracellular vesicles in diagnostics and prognosis of malignant neoplasms of the female reproductive system: current data and future perspectives</article-title><trans-title-group xml:lang="ru"><trans-title>Внеклеточные везикулы в диагностике и прогнозировании злокачественных новообразований женской репродуктивной системы: современные данные и перспективы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7519-2969</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербачева</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Sherbacheva</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щербачева Алина Олеговна</p><p>305041 Курск, ул. Карла Маркса, д. 3</p></bio><bio xml:lang="en"><p>Alina O. Sherbacheva</p><p>3 Karl Marx Str., Kursk 305041</p></bio><email xlink:type="simple">shherbacheva022@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-8534-3350</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сибирцев</surname><given-names>Д. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Sibirtsev</surname><given-names>D. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сибирцев Дмитрий Максимович</p><p>400066, Волгоград, площадь Павших Борцов, д. 1</p></bio><bio xml:lang="en"><p>Dmitriy M. Sibirtsev</p><p>1 Pavshikh Bortsov Square, Volgograd 400066</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-8961-9721</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савин</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Savin</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Савин Никита Николаевич</p><p>117513, Москва, ул. Островитянова, д. 1</p></bio><bio xml:lang="en"><p>Nikita N. Savin</p><p>1 Ostrovityanova Str., Moscow 117513</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-1785-4123</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцева</surname><given-names>Я. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rumyantseva</surname><given-names>Ya. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Румянцева Яна Вячеславовна</p><p>344022 Ростов-на-Дону, Нахичеванский переулок, д. 29</p></bio><bio xml:lang="en"><p>Yana V. Rumyantseva</p><p>29 Nakhichevansky Lane, Rostov-on-Don 344022</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-7455-0755</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бражкина</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Brazhkina</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бражкина Анастасия Евгеньевна</p><p>344022 Ростов-на-Дону, Нахичеванский переулок, д. 29</p></bio><bio xml:lang="en"><p>Anastasia E. Brazhkina</p><p>29 Nakhichevansky Lane, Rostov-on-Don 344022</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-0172-9869</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Качалова</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kachalova</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Качалова Виктория Максимовна</p><p>394036 Воронеж, Студенческая ул., д. 10</p></bio><bio xml:lang="en"><p>Victoria M. Kachalova</p><p>10 Studencheskaya Str., Voronezh 394036</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4296-548X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамай</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamay</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамай Алина Владимировна</p><p>295007 Симферополь, проспект Академика Вернадского, д. 4</p></bio><bio xml:lang="en"><p>Alina V. Mamay</p><p>295007 Simferopol, Academician Vernadsky Avenue, 4</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7468-6135</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Типтева</surname><given-names>Д. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Tipteva</surname><given-names>D. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Типтева Дарья Денисовна</p><p>450008 Уфа, ул. Ленина, д. 3</p></bio><bio xml:lang="en"><p>Darya D. Tipteva</p><p>3 Lenin Str., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-3028-0546</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хитрина</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khitrina</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хитрина Юлия Викторовна</p><p>450008 Уфа, ул. Ленина, д. 3</p></bio><bio xml:lang="en"><p>Yulia V. Khitrina</p><p>3 Lenin Str., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-0915-0064</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жуков</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhukov</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жуков Никита Геннадиевич</p><p>362019 Республика Северная Осетия–Алания, Владикавказ, Пушкинская ул., д. 40</p></bio><bio xml:lang="en"><p>Nikita G. Zhukov</p><p>40 Pushkinskaya Str., Vladikavkaz, Republic of North Ossetia–Alania 362019</p></bio><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-2404-4697</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Изотов</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Izotov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Изотов Родион Андреевич</p><p>191015 Санкт-Петербург, Кирочная ул., д. 41</p></bio><bio xml:lang="en"><p>Rodion A. Izotov</p><p>41 Kirochnaya Str., Saint Petersburg 191015</p></bio><xref ref-type="aff" rid="aff-9"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-5063-4004</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юлдашева</surname><given-names>Э. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Yuldasheva</surname><given-names>E. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юлдашева Эльвина Рафитовна</p><p>450008 Уфа, ул. Ленина, д. 3</p></bio><bio xml:lang="en"><p>Elvina R. Yuldasheva</p><p>3 Lenin Str., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-4152-1340</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Анохина</surname><given-names>Я. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Anokhina</surname><given-names>Ya. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анохина Яна Андреевна</p><p>344022 Ростов-на-Дону, Нахичеванский переулок, д. 29</p></bio><bio xml:lang="en"><p>Yana A. Anokhina</p><p>29 Nakhichevansky Lane, Rostov-on-Don 344022</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Курский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kursk State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГБОУ ВО «Воронежский государственный медицинский университет имени Н.Н. Бурденко» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Burdenko Voronezh State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vernadsky Crimean Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГБОУ ВО «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North Ossetian State Medical Academy, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>01</month><year>2026</year></pub-date><volume>19</volume><issue>6</issue><fpage>942</fpage><lpage>965</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Sherbacheva A.O., Sibirtsev D.M., Savin N.N., Rumyantseva Y.V., Brazhkina A.E., Kachalova V.M., Mamay A.V., Tipteva D.D., Khitrina Y.V., Zhukov N.G., Izotov R.A., Yuldasheva E.R., Anokhina Y.A., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Щербачева А.О., Сибирцев Д.М., Савин Н.Н., Румянцева Я.В., Бражкина А.Е., Качалова В.М., Мамай А.В., Типтева Д.Д., Хитрина Ю.В., Жуков Н.Г., Изотов Р.А., Юлдашева Э.Р., Анохина Я.А.</copyright-holder><copyright-holder xml:lang="en">Sherbacheva A.O., Sibirtsev D.M., Savin N.N., Rumyantseva Y.V., Brazhkina A.E., Kachalova V.M., Mamay A.V., Tipteva D.D., Khitrina Y.V., Zhukov N.G., Izotov R.A., Yuldasheva E.R., Anokhina Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/2514">https://www.gynecology.su/jour/article/view/2514</self-uri><abstract><p>Malignant neoplasms of the female reproductive system remain a significant global health concern, ranking among the leading causes of cancer incidence and mortality in women. Despite advances in the field of gynecologic oncology, early diagnosis and prognosis of such diseases continue to pose substantial challenges. In recent years, extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, have been increasingly attracted attention as key mediators of intercellular communication and carriers of biologically active molecules. EVs transport microRNAs, long non-coding RNAs, proteins, and other molecules that influence critical carcinogenic processes such as proliferation, angiogenesis, metastasis, and the development of chemoresistance. This review summarizes current data on the EVs role in the pathogenesis and progression of cervical, endometrial, and ovarian cancers. The diagnostic and prognostic potential of EV-associated biomolecular components is examined, with evidence from preclinical and clinical studies highlighting their promise as biomarkers. The review also discusses the prospects for clinical application of EVs, emphasizing the challenges of methodological standardization and the need for multicenter studies to validate their clinical utility. Additionally, the importance of integrating omics technologies and bioinformatics approaches is underscored as essential for improving patient stratification and advancing personalized therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Злокачественные новообразования женской репродуктивной системы остаются серьезной проблемой глобального здравоохранения, занимая одно из ведущих мест в структуре онкологической заболеваемости и смертности среди женщин. Несмотря на достижения в области онкогинекологии, ранняя диагностика и прогнозирование исходов заболевания по-прежнему представляют значительные трудности. В последние годы внеклеточные везикулы (ВВ), включая экзосомы, микровезикулы и апоптотические тельца, привлекли внимание исследователей как важные посредники межклеточной коммуникации и носители биологически активных молекул. ВВ транспортируют микроРНК, длинные некодирующие РНК, белки и другие молекулы, влияющие на ключевые процессы канцерогенеза, такие как пролиферация, ангиогенез, метастазирование и развитие химиорезистентности. В обзоре представлены актуальные данные о роли ВВ в патогенезе и прогрессировании рака шейки матки, эндометрия и яичников. Рассмотрены диагностические и прогностические возможности биомолекулярных компонентов ВВ, продемонстрированы результаты доклинических и клинических исследований, подчеркивающие потенциал этих биомаркеров. Обсуждаются перспективы применения ВВ в клинической практике, включая вызовы стандартизации методик и необходимость мультицентровых исследований для подтверждения их клинической ценности. Также отмечена важность интеграции омических технологий и биоинформатических подходов для более точной стратификации пациенток и персонализации терапии.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>внеклеточные везикулы</kwd><kwd>ВВ</kwd><kwd>экзосомы</kwd><kwd>гинекологические опухоли</kwd><kwd>рак шейки матки</kwd><kwd>рак эндометрия</kwd><kwd>рак яичников</kwd><kwd>биомаркеры</kwd><kwd>микроРНК</kwd><kwd>длинные некодирующие РНК</kwd><kwd>диагностика</kwd><kwd>прогнозирование</kwd><kwd>онкогинекология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>extracellular vesicles</kwd><kwd>EVs</kwd><kwd>exosomes</kwd><kwd>gynecological cancers</kwd><kwd>cervical cancer</kwd><kwd>endometrial cancer</kwd><kwd>ovarian cancer</kwd><kwd>biomarkers</kwd><kwd>microRNAs</kwd><kwd>long non-coding RNAs</kwd><kwd>diagnosis</kwd><kwd>prognosis</kwd><kwd>gynecologic oncology</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Жилина Н.И., Шрамко С.В. Злокачественные новообразования женских репродуктивных органов в динамике 2011–2020 на примере Новокузнецка. Социальные аспекты здоровья населения. 2022;68(3):11. https://doi.org/10.21045/2071-5021-2022-68-3-11.</mixed-citation><mixed-citation xml:lang="en">Zhilina N.M., Shramko S.V. Malignant neoplasms of the female reproductive organs in the dynamics of 2011–2020 on the example of Novokuznetsk. [Zlokachestvennye novoobrazovaniya zhenskih reproduktivnyh organov v dinamike 2011–2020 na primere Novokuznecka]. Sotsialnye aspekty zdorovya naseleniya. 2022;68(3):11. (In Russ.). https://doi.org/10.21045/2071-5021-2022-68-3-11.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu B., Gu H., Mao Z. et al. Global burden of gynaecological cancers in 2022 and projections to 2050. J Glob Health. 2024;14:04155. https://doi.org/10.7189/jogh.14.04155.</mixed-citation><mixed-citation xml:lang="en">Zhu B., Gu H., Mao Z. et al. Global burden of gynaecological cancers in 2022 and projections to 2050. J Glob Health. 2024;14:04155. https://doi.org/10.7189/jogh.14.04155.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кононова Г.А., Жуйкова Л.Д., Ананина О.А. и др. Рак репродуктивной системы у женщин Республики Тыва. Эпидемиологические особенности. Сибирский онкологический журнал. 2024;23(3):5–14. https://doi.org/10.21294/1814-4861-2024-23-3-5-14.</mixed-citation><mixed-citation xml:lang="en">Kononova G.A., Zhuikova L.D., Ananina O.A. et al. Reproductive system cancer in females of the Tyva Republic. Epidemiological characteristics. [Rak reproduktivnoj sistemy u zhenshchin Respubliki Tyva. Epidemiologicheskie osobennosti]. Sibirskij onkologicheskij zhurnal. 2024;23(3):5–14. (In Russ.). https://doi.org/10.21294/1814-4861-2024-23-3-5-14.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Чернобровкина А.Е. Заболеваемость злокачественными новообразованиями женской половой сферы населения Санкт-Петербурга. Здоровье населения и среда обитания – ЗНиСО. 2022;1(1):29–35. https://doi.org/10.35627/2219-5238/2022-30-1-29-35.</mixed-citation><mixed-citation xml:lang="en">Chernobrovkina A.E. The Incidence of malignant tumors of the female reproductive system in Saint Petersburg. [Zabolevaemost' zlokachestvennymi novoobrazovaniyami zhenskoj polovoj sfery naseleniya Sankt-Peterburga]. Zdorov'e naseleniya i sreda obitaniya – ZNiSO. 2022;1(1):29–35. (In Russ.). https://doi.org/10.35627/2219-5238/2022-30-1-29-35.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Александрова Л.М., Грецова О.П., Петрова Г.В. и др. Выявление злокачественных новообразований молочной железы и органов женской репродуктивной системы при диспансеризации определенных групп взрослого населения. Профилактическая медицина. 2016;19(3):4–11. https://doi.org/10.17116/profmed20161934-11.</mixed-citation><mixed-citation xml:lang="en">Aleksandrova L.M., Gretsova O.P., Petrova G.V. et al. Detection of malignant tumors of the breast and female reproductive organs during medical prophylactic examination of certain adult population groups. [Vyyavlenie zlokachestvennyh novoobrazovanij molochnoj zhelezy i organov zhenskoj reproduktivnoj sistemy pri dispanserizacii opredelennyh grupp vzroslogo naseleniya]. Profilakticheskaya medicina. 2016;19(3):4–11. (In Russ.). https://doi.org/10.17116/profmed20161934-11.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Краевая Е.Е., Силачев Д.Н., Безнощенко О.С. и др. Влияние внеклеточных везикул фолликулярной жидкости на коагуляционный гемостаз яичника. Проблемы репродукции. 2020;26(2):18–26. https://doi.org/10.17116/repro20202602118.</mixed-citation><mixed-citation xml:lang="en">Kraevaya E.E., Silachev D.N., Beznoshchenko O.S. et al. Effect of extracellular vesicles of follicular fluid on ovarian coagulation hemostasis. [Vliyanie vnekletochnyh vezikul follikulyarnoj zhidkosti na koagulyacionnyj gemostaz yaichnika]. Problemy reprodukcii. 2020;26(2):18–26. (In Russ.). https://doi.org/10.17116/repro20202602118.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rafieezadeh D., Rafieezadeh A. Extracellular vesicles and their therapeutic applications: a review article (part1). Int J Physiol Pathophysiol Pharmacol. 2024;16(1):1–9. https://doi.org/10.62347/QPAG5693.</mixed-citation><mixed-citation xml:lang="en">Rafieezadeh D., Rafieezadeh A. Extracellular vesicles and their therapeutic applications: a review article (part1). Int J Physiol Pathophysiol Pharmacol. 2024;16(1):1–9. https://doi.org/10.62347/QPAG5693.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng Y., Qiu Y., Jiang W. et al. Biological features of extracellular vesicles and challenges. Front Cell Dev Biol. 2022;10:816698. https://doi.org/10.3389/fcell.2022.816698.</mixed-citation><mixed-citation xml:lang="en">Zeng Y., Qiu Y., Jiang W. et al. Biological features of extracellular vesicles and challenges. Front Cell Dev Biol. 2022;10:816698. https://doi.org/10.3389/fcell.2022.816698.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fusco C., De Rosa G., Spatocco I. et al. Extracellular vesicles as human therapeutics: a scoping review of the literature. J Extracell Vesicles. 2024;13(5):e12433. https://doi.org/10.1002/jev2.12433.</mixed-citation><mixed-citation xml:lang="en">Fusco C., De Rosa G., Spatocco I. et al. Extracellular vesicles as human therapeutics: a scoping review of the literature. J Extracell Vesicles. 2024;13(5):e12433. https://doi.org/10.1002/jev2.12433.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng M., Hou L., Ma Y. et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer. 2019;18(1):76. https://doi.org/10.1186/s12943-019-0999-x.</mixed-citation><mixed-citation xml:lang="en">Zheng M., Hou L., Ma Y. et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer. 2019;18(1):76. https://doi.org/10.1186/s12943-019-0999-x.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang L., Huang Q., Chang J. et al. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res. 2011;37(7):387–98. https://doi.org/10.3109/01902148.2010.492068.</mixed-citation><mixed-citation xml:lang="en">Jiang L., Huang Q., Chang J. et al. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res. 2011;37(7):387–98. https://doi.org/10.3109/01902148.2010.492068.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bi Q., Tang S., Xia L. et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012;7(6):e40169. https://doi.org/10.1371/journal.pone.0040169.</mixed-citation><mixed-citation xml:lang="en">Bi Q., Tang S., Xia L. et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012;7(6):e40169. https://doi.org/10.1371/journal.pone.0040169.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lv A., Tu Z., Huang Y. et al. Circulating exosomal miR-125a-5p as a novel biomarker for cervical cancer. Oncol Lett. 2021;21(1):54. https://doi.org/10.3892/ol.2020.12316.</mixed-citation><mixed-citation xml:lang="en">Lv A., Tu Z., Huang Y. et al. Circulating exosomal miR-125a-5p as a novel biomarker for cervical cancer. Oncol Lett. 2021;21(1):54. https://doi.org/10.3892/ol.2020.12316.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X., Tang S., Le S.Y. et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008;3(7):e2557. https://doi.org/10.1371/journal.pone.0002557.</mixed-citation><mixed-citation xml:lang="en">Wang X., Tang S., Le S.Y. et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008;3(7):e2557. https://doi.org/10.1371/journal.pone.0002557.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yao Q., Xu H., Zhang Q.Q. et al. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun. 2009;388(3):539–42. https://doi.org/10.1016/j.bbrc.2009.08.044.</mixed-citation><mixed-citation xml:lang="en">Yao Q., Xu H., Zhang Q.Q. et al. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun. 2009;388(3):539–42. https://doi.org/10.1016/j.bbrc.2009.08.044.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J., Sun H., Wang X. et al. Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int J Mol Sci. 2014;15(1):758–73. https://doi.org/10.3390/ijms15010758.</mixed-citation><mixed-citation xml:lang="en">Liu J., Sun H., Wang X. et al. Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int J Mol Sci. 2014;15(1):758–73. https://doi.org/10.3390/ijms15010758.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J., Liu S.C., Luo X.H. et al. Exosomal long noncoding RNAs are differentially expressed in the cervicovaginal lavage samples of cervical cancer patients. J Clin Lab Anal. 2016;30(6):1116–21. https://doi.org/10.1002/jcla.21990.</mixed-citation><mixed-citation xml:lang="en">Zhang J., Liu S.C., Luo X.H. et al. Exosomal long noncoding RNAs are differentially expressed in the cervicovaginal lavage samples of cervical cancer patients. J Clin Lab Anal. 2016;30(6):1116–21. https://doi.org/10.1002/jcla.21990.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yang L., Bai H.-S., Deng Y., Fan L. High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur Rev Med Pharmacol Sci. 2015;19(17):3187–93.</mixed-citation><mixed-citation xml:lang="en">Yang L., Bai H.-S., Deng Y., Fan L. High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur Rev Med Pharmacol Sci. 2015;19(17):3187–93.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H.J., Lee D.W., Yim G.W. et al. Long non-coding RNA HOTAIR is associated with human cervical cancer progression. Int J Oncol. 2015;46(2):521–30. https://doi.org/10.3892/ijo.2014.2758.</mixed-citation><mixed-citation xml:lang="en">Kim H.J., Lee D.W., Yim G.W. et al. Long non-coding RNA HOTAIR is associated with human cervical cancer progression. Int J Oncol. 2015;46(2):521–30. https://doi.org/10.3892/ijo.2014.2758.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J., Yao T., Wang Y. et al. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther. 2016;17(1):104–13. https://doi.org/10.1080/15384047.2015.1108496.</mixed-citation><mixed-citation xml:lang="en">Zhang J., Yao T., Wang Y. et al. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther. 2016;17(1):104–13. https://doi.org/10.1080/15384047.2015.1108496.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Liang L.J., Yang Y., Wei W.F. et al. Tumor-secreted exosomal Wnt2B activates fibroblasts to promote cervical cancer progression. Oncogenesis. 2021;10(3):30. https://doi.org/10.1038/s41389-021-00319-w.</mixed-citation><mixed-citation xml:lang="en">Liang L.J., Yang Y., Wei W.F. et al. Tumor-secreted exosomal Wnt2B activates fibroblasts to promote cervical cancer progression. Oncogenesis. 2021;10(3):30. https://doi.org/10.1038/s41389-021-00319-w.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Someya M., Hasegawa T., Tsuchiya T. et al. Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy. Med Mol Morphol. 2023;56(1):38–45. https://doi.org/10.1007/s00795-022-00338-5.</mixed-citation><mixed-citation xml:lang="en">Someya M., Hasegawa T., Tsuchiya T. et al. Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy. Med Mol Morphol. 2023;56(1):38–45. https://doi.org/10.1007/s00795-022-00338-5.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou C.F., Ma J., Huang L. et al. Correction to: cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 2022;41(8):1231–33. https://doi.org/10.1038/s41388-021-02165-x.</mixed-citation><mixed-citation xml:lang="en">Zhou C.F., Ma J., Huang L. et al. Correction to: cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 2022;41(8):1231–33. https://doi.org/10.1038/s41388-021-02165-x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou C., Wei W., Ma J. et al. Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Mol Ther. 2021;29(4):1512–28. https://doi.org/10.1016/j.ymthe.2020.12.034.</mixed-citation><mixed-citation xml:lang="en">Zhou C., Wei W., Ma J. et al. Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Mol Ther. 2021;29(4):1512–28. https://doi.org/10.1016/j.ymthe.2020.12.034.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou C., Zhang Y., Yan R. et al. Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. Cell Death Differ. 2021;28(2):715–29. https://doi.org/10.1038/s41418-020-00618-6.</mixed-citation><mixed-citation xml:lang="en">Zhou C., Zhang Y., Yan R. et al. Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. Cell Death Differ. 2021;28(2):715–29. https://doi.org/10.1038/s41418-020-00618-6.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ding X.Z., Zhang S.Q., Deng X.L., Qiang J.H. Serum exosomal lncRNA DLX6-AS1 is a promising biomarker for prognosis prediction of cervical cancer. Technol Cancer Res Treat. 2021;20:1533033821990060. https://doi.org/10.1177/1533033821990060.</mixed-citation><mixed-citation xml:lang="en">Ding X.Z., Zhang S.Q., Deng X.L., Qiang J.H. Serum exosomal lncRNA DLX6-AS1 is a promising biomarker for prognosis prediction of cervical cancer. Technol Cancer Res Treat. 2021;20:1533033821990060. https://doi.org/10.1177/1533033821990060.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Guo Y., Wang X., Wang K., He Y. Appraising the value of serum and serum-derived exosomal LncRNA-EXOC7 as a promising biomarker in cervical cancer. Clin Lab. 2020;66(7). https://doi.org/10.7754/Clin.Lab.2019.191203.</mixed-citation><mixed-citation xml:lang="en">Guo Y., Wang X., Wang K., He Y. Appraising the value of serum and serum-derived exosomal LncRNA-EXOC7 as a promising biomarker in cervical cancer. Clin Lab. 2020;66(7). https://doi.org/10.7754/Clin.Lab.2019.191203.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Qiu J.J., Sun S.G., Tang X.Y. et al. Extracellular vesicular Wnt7b mediates HPV E6-induced cervical cancer angiogenesis by activating the β-catenin signaling pathway. J Exp Clin Cancer Res. 2020;39(1):260. https://doi.org/10.1186/s13046-020-01745-1.</mixed-citation><mixed-citation xml:lang="en">Qiu J.J., Sun S.G., Tang X.Y. et al. Extracellular vesicular Wnt7b mediates HPV E6-induced cervical cancer angiogenesis by activating the β-catenin signaling pathway. J Exp Clin Cancer Res. 2020;39(1):260. https://doi.org/10.1186/s13046-020-01745-1.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Shi Y, Wang W, Yang B, Tian H. ATF1 and RAS in exosomes are potential clinical diagnostic markers for cervical cancer. Cell Biochem Funct. 2017;35(7):477–83. https://doi.org/10.1002/cbf.3307.</mixed-citation><mixed-citation xml:lang="en">Shi Y, Wang W, Yang B, Tian H. ATF1 and RAS in exosomes are potential clinical diagnostic markers for cervical cancer. Cell Biochem Funct. 2017;35(7):477–83. https://doi.org/10.1002/cbf.3307.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L., Li H., Yuan M. et al. Cervical cancer cells-secreted exosomal microRNA-221-3p promotes invasion, migration and angiogenesis of microvascular endothelial cells in cervical cancer by down-regulating MAPK10 expression. Cancer Manag Res. 2019;11:10307–19. https://doi.org/10.2147/CMAR.S221527.</mixed-citation><mixed-citation xml:lang="en">Zhang L., Li H., Yuan M. et al. Cervical cancer cells-secreted exosomal microRNA-221-3p promotes invasion, migration and angiogenesis of microvascular endothelial cells in cervical cancer by down-regulating MAPK10 expression. Cancer Manag Res. 2019;11:10307–19. https://doi.org/10.2147/CMAR.S221527.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Wu L., Tian J. et al. Cervical cancer cells-derived extracellular vesicles containing microRNA-146a-5p affect actin dynamics to promote cervical cancer metastasis by activating the Hippo-YAP signaling pathway via WWC2. J Oncol. 2022;2022:4499876. https://doi.org/10.1155/2022/4499876.</mixed-citation><mixed-citation xml:lang="en">Wang W., Wu L., Tian J. et al. Cervical cancer cells-derived extracellular vesicles containing microRNA-146a-5p affect actin dynamics to promote cervical cancer metastasis by activating the Hippo-YAP signaling pathway via WWC2. J Oncol. 2022;2022:4499876. https://doi.org/10.1155/2022/4499876.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Yan X., Zhang S., Jia J. et al. Exosomal MiR-423-3p inhibits macrophage M2 polarization to suppress the malignant progression of cervical cancer. Pathol Res Pract. 2022;235:153882. https://doi.org/10.1016/j.prp.2022.153882.</mixed-citation><mixed-citation xml:lang="en">Yan X., Zhang S., Jia J. et al. Exosomal MiR-423-3p inhibits macrophage M2 polarization to suppress the malignant progression of cervical cancer. Pathol Res Pract. 2022;235:153882. https://doi.org/10.1016/j.prp.2022.153882.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang L., Hong L., Yang W. et al. Co-expression network analysis of the lncRNAs and mRNAs associated with cervical cancer progression. Arch Med Sci. 2019;15(3):754–64. https://doi.org/10.5114/aoms.2019.84740.</mixed-citation><mixed-citation xml:lang="en">Jiang L., Hong L., Yang W. et al. Co-expression network analysis of the lncRNAs and mRNAs associated with cervical cancer progression. Arch Med Sci. 2019;15(3):754–64. https://doi.org/10.5114/aoms.2019.84740.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Huang X., Liu X., Du B. et al. LncRNA LINC01305 promotes cervical cancer progression through KHSRP and exosome-mediated transfer. Aging (Albany NY). 2021;13(15):19230–42. https://doi.org/10.18632/aging.202565.</mixed-citation><mixed-citation xml:lang="en">Huang X., Liu X., Du B. et al. LncRNA LINC01305 promotes cervical cancer progression through KHSRP and exosome-mediated transfer. Aging (Albany NY). 2021;13(15):19230–42. https://doi.org/10.18632/aging.202565.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Y., Sun X., Mao C. et al. Upregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration. Cancer Med. 2017;6(2):471–82. https://doi.org/10.1002/cam4.994.</mixed-citation><mixed-citation xml:lang="en">Hu Y., Sun X., Mao C. et al. Upregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration. Cancer Med. 2017;6(2):471–82. https://doi.org/10.1002/cam4.994.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Lei L., Mou Q. Exosomal taurine up-regulated 1 promotes angiogenesis and endothelial cell proliferation in cervical cancer. Cancer Biol Ther. 2020;21(8):717–25. https://doi.org/10.1080/15384047.2020.1764318.</mixed-citation><mixed-citation xml:lang="en">Lei L., Mou Q. Exosomal taurine up-regulated 1 promotes angiogenesis and endothelial cell proliferation in cervical cancer. Cancer Biol Ther. 2020;21(8):717–25. https://doi.org/10.1080/15384047.2020.1764318.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Mo Y., Liang Z., Lan L. et al. Extracellular vesicles derived from cervical cancer cells carrying MCM3AP-AS1 promote angiogenesis and tumor growth in cervical cancer via the miR-93/p21 axis. Exp Cell Res. 2023;428(2):113621. https://doi.org/10.1016/j.yexcr.2023.113621.</mixed-citation><mixed-citation xml:lang="en">Mo Y., Liang Z., Lan L. et al. Extracellular vesicles derived from cervical cancer cells carrying MCM3AP-AS1 promote angiogenesis and tumor growth in cervical cancer via the miR-93/p21 axis. Exp Cell Res. 2023;428(2):113621. https://doi.org/10.1016/j.yexcr.2023.113621.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bhat A., Yadav J., Thakur K. et al. Transcriptome analysis of cervical cancer exosomes and detection of HPVE6*I transcripts in exosomal RNA. BMC Cancer. 2022;22(1):164. https://doi.org/10.1186/s12885-022-09262-4.</mixed-citation><mixed-citation xml:lang="en">Bhat A., Yadav J., Thakur K. et al. Transcriptome analysis of cervical cancer exosomes and detection of HPVE6*I transcripts in exosomal RNA. BMC Cancer. 2022;22(1):164. https://doi.org/10.1186/s12885-022-09262-4.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Acevedo-Sánchez V., Martínez-Ruiz R.S., Aguilar-Ruíz S.R. et al. Quantitative proteomics for the identification of differentially expressed proteins in the extracellular vesicles of cervical cancer cells. Viruses. 2023;15(3):702. https://doi.org/10.3390/v15030702.</mixed-citation><mixed-citation xml:lang="en">Acevedo-Sánchez V., Martínez-Ruiz R.S., Aguilar-Ruíz S.R. et al. Quantitative proteomics for the identification of differentially expressed proteins in the extracellular vesicles of cervical cancer cells. Viruses. 2023;15(3):702. https://doi.org/10.3390/v15030702.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou L., Wang W., Wang F. et al. Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Mol Cancer. 2021;20(1):57. https://doi.org/10.1186/s12943-021-01352-4.</mixed-citation><mixed-citation xml:lang="en">Zhou L., Wang W., Wang F. et al. Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Mol Cancer. 2021;20(1):57. https://doi.org/10.1186/s12943-021-01352-4.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Fan X., Cao M., Liu C. et al. Three plasma-based microRNAs as potent diagnostic biomarkers for endometrial cancer. Cancer Biomark. 2021;31(2):127–38. https://doi.org/10.3233/CBM-200972.</mixed-citation><mixed-citation xml:lang="en">Fan X., Cao M., Liu C. et al. Three plasma-based microRNAs as potent diagnostic biomarkers for endometrial cancer. Cancer Biomark. 2021;31(2):127–38. https://doi.org/10.3233/CBM-200972.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Daugaard I., Sanders K.J., Idica A. et al. miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis. 2017;6(7):e366. https://doi.org/10.1038/oncsis.2017.66.</mixed-citation><mixed-citation xml:lang="en">Daugaard I., Sanders K.J., Idica A. et al. miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis. 2017;6(7):e366. https://doi.org/10.1038/oncsis.2017.66.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Hu H., Jiang L., Kang X. et al. Extracellular vesicles derived from lung cancer cells promote the progression of lung cancer by delivering miR-151a-5p. Exp Cell Res. 2023;425(1):113526. https://doi.org/10.1016/j.yexcr.2023.113526.</mixed-citation><mixed-citation xml:lang="en">Hu H., Jiang L., Kang X. et al. Extracellular vesicles derived from lung cancer cells promote the progression of lung cancer by delivering miR-151a-5p. Exp Cell Res. 2023;425(1):113526. https://doi.org/10.1016/j.yexcr.2023.113526.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Fan X., Zou X., Liu C. et al. MicroRNA expression profile in serum reveals novel diagnostic biomarkers for endometrial cancer. Biosci Rep. 2021;41(6):BSR20210111. https://doi.org/10.1042/BSR20210111.</mixed-citation><mixed-citation xml:lang="en">Fan X., Zou X., Liu C. et al. MicroRNA expression profile in serum reveals novel diagnostic biomarkers for endometrial cancer. Biosci Rep. 2021;41(6):BSR20210111. https://doi.org/10.1042/BSR20210111.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Jing L., Hua X., Yuanna D. et al. Exosomal miR-499a-5p inhibits endometrial cancer growth and metastasis via targeting VAV3. Cancer Manag Res. 2020;12:13541–52. https://doi.org/10.2147/CMAR.S283747.</mixed-citation><mixed-citation xml:lang="en">Jing L., Hua X., Yuanna D. et al. Exosomal miR-499a-5p inhibits endometrial cancer growth and metastasis via targeting VAV3. Cancer Manag Res. 2020;12:13541–52. https://doi.org/10.2147/CMAR.S283747.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang N., Wang Y., Liu H., Shen W. Extracellular vesicle encapsulated microRNA-320a inhibits endometrial cancer by suppression of the HIF1α/VEGFA axis. Exp Cell Res. 2020;394(2):112113. https://doi.org/10.1016/j.yexcr.2020.112113.</mixed-citation><mixed-citation xml:lang="en">Zhang N., Wang Y., Liu H., Shen W. Extracellular vesicle encapsulated microRNA-320a inhibits endometrial cancer by suppression of the HIF1α/VEGFA axis. Exp Cell Res. 2020;394(2):112113. https://doi.org/10.1016/j.yexcr.2020.112113.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Fan J.T., Zhou Z.Y., Luo Y.L. et al. Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway. Neoplasia. 2021;23(7):692–703. https://doi.org/10.1016/j.neo.2021.05.004.</mixed-citation><mixed-citation xml:lang="en">Fan J.T., Zhou Z.Y., Luo Y.L. et al. Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway. Neoplasia. 2021;23(7):692–703. https://doi.org/10.1016/j.neo.2021.05.004.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Seagle B.L., Alexander A.L., Lantsman T., Shahabi S. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol. 2018;218(3):329.e1–329.e15. https://doi.org/10.1016/j.ajog.2017.11.601.</mixed-citation><mixed-citation xml:lang="en">Seagle B.L., Alexander A.L., Lantsman T., Shahabi S. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol. 2018;218(3):329.e1–329.e15. https://doi.org/10.1016/j.ajog.2017.11.601.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Roman-Canal B., Moiola C.P., Gatius S. et al. EV-associated miRNAs from peritoneal lavage are a source of biomarkers in endometrial cancer. Cancers (Basel). 2019;11(6):839. https://doi.org/10.3390/cancers11060839.</mixed-citation><mixed-citation xml:lang="en">Roman-Canal B., Moiola C.P., Gatius S. et al. EV-associated miRNAs from peritoneal lavage are a source of biomarkers in endometrial cancer. Cancers (Basel). 2019;11(6):839. https://doi.org/10.3390/cancers11060839.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Xu H., Gong Z., Shen Y. et al. Circular RNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer. Epigenomics. 2018;10(2):187–97. https://doi.org/10.2217/epi-2017-0109.</mixed-citation><mixed-citation xml:lang="en">Xu H., Gong Z., Shen Y. et al. Circular RNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer. Epigenomics. 2018;10(2):187–97. https://doi.org/10.2217/epi-2017-0109.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Wakabayashi I., Marumo M., Ekawa K., Daimon T. Differences in serum and plasma levels of microRNAs and their time-course changes after blood collection. Pract Lab Med. 2024;39:e00376. https://doi.org/10.1016/j.plabm.2024.e00376.</mixed-citation><mixed-citation xml:lang="en">Wakabayashi I., Marumo M., Ekawa K., Daimon T. Differences in serum and plasma levels of microRNAs and their time-course changes after blood collection. Pract Lab Med. 2024;39:e00376. https://doi.org/10.1016/j.plabm.2024.e00376.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng L., Sun X., Scicluna B.J. et al. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int. 2014;86(2):433–44. https://doi.org/10.1038/ki.2013.502.</mixed-citation><mixed-citation xml:lang="en">Cheng L., Sun X., Scicluna B.J. et al. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int. 2014;86(2):433–44. https://doi.org/10.1038/ki.2013.502.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Whitehouse J.S., Weigelt J.A. Diagnostic peritoneal lavage: a review of indications, technique, and interpretation. Scand J Trauma Resusc Emerg Med. 2009;17:13. https://doi.org/10.1186/1757-7241-17-13.</mixed-citation><mixed-citation xml:lang="en">Whitehouse J.S., Weigelt J.A. Diagnostic peritoneal lavage: a review of indications, technique, and interpretation. Scand J Trauma Resusc Emerg Med. 2009;17:13. https://doi.org/10.1186/1757-7241-17-13.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Mariscal J., Fernandez-Puente P., Calamia V. et al. Proteomic characterization of epithelial-like extracellular vesicles in advanced endometrial cancer. J Proteome Res. 2019;18(3):1043–53. https://doi.org/10.1021/acs.jproteome.8b00750.</mixed-citation><mixed-citation xml:lang="en">Mariscal J., Fernandez-Puente P., Calamia V. et al. Proteomic characterization of epithelial-like extracellular vesicles in advanced endometrial cancer. J Proteome Res. 2019;18(3):1043–53. https://doi.org/10.1021/acs.jproteome.8b00750.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Herrero C., de la Fuente A., Casas-Arozamena C. et al. Extracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial cancer. Cancers (Basel). 2019;11(12):2000. https://doi.org/10.3390/cancers11122000.</mixed-citation><mixed-citation xml:lang="en">Herrero C., de la Fuente A., Casas-Arozamena C. et al. Extracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial cancer. Cancers (Basel). 2019;11(12):2000. https://doi.org/10.3390/cancers11122000.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Li B.L., Lu W., Qu J.J. et al. Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis. J Cell Physiol. 2019;234(3):2943–53. https://doi.org/10.1002/jcp.27111.</mixed-citation><mixed-citation xml:lang="en">Li B.L., Lu W., Qu J.J. et al. Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis. J Cell Physiol. 2019;234(3):2943–53. https://doi.org/10.1002/jcp.27111.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Srivastava A., Moxley K., Ruskin R. et al. A non-invasive liquid biopsy screening of urine-derived exosomes for miRNAs as biomarkers in endometrial cancer patients. AAPS J. 2018;20(5):82. https://doi.org/10.1208/s12248-018-0220-y.</mixed-citation><mixed-citation xml:lang="en">Srivastava A., Moxley K., Ruskin R. et al. A non-invasive liquid biopsy screening of urine-derived exosomes for miRNAs as biomarkers in endometrial cancer patients. AAPS J. 2018;20(5):82. https://doi.org/10.1208/s12248-018-0220-y.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Li F., Liang A., Lv Y. et al. MicroRNA-200c inhibits epithelial-mesenchymal transition by targeting the BMI-1 gene through the phospho-AKT pathway in endometrial carcinoma cells in vitro. Med Sci Monit. 2017;23:5139–49. https://doi.org/10.12659/msm.907207.</mixed-citation><mixed-citation xml:lang="en">Li F., Liang A., Lv Y. et al. MicroRNA-200c inhibits epithelial-mesenchymal transition by targeting the BMI-1 gene through the phospho-AKT pathway in endometrial carcinoma cells in vitro. Med Sci Monit. 2017;23:5139–49. https://doi.org/10.12659/msm.907207.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Sánchez-Tilló E., Lu X. et al. The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression. J Biol Chem. 2014;289(7):4116–25. https://doi.org/10.1074/jbc.M113.533505.</mixed-citation><mixed-citation xml:lang="en">Liu Y., Sánchez-Tilló E., Lu X. et al. The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression. J Biol Chem. 2014;289(7):4116–25. https://doi.org/10.1074/jbc.M113.533505.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Song Y., Wang M., Tong H. et al. Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression. Oncogene. 2021;40(3):633–46. https://doi.org/10.1038/s41388-020-01555-x.</mixed-citation><mixed-citation xml:lang="en">Song Y., Wang M., Tong H. et al. Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression. Oncogene. 2021;40(3):633–46. https://doi.org/10.1038/s41388-020-01555-x.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Sommella E., Capaci V., Aloisio M. et al. A label-free proteomic approach for the identification of biomarkers in the exosome of endometrial cancer serum. Cancers (Basel). 2022;14(24):6262. https://doi.org/10.3390/cancers14246262.</mixed-citation><mixed-citation xml:lang="en">Sommella E., Capaci V., Aloisio M. et al. A label-free proteomic approach for the identification of biomarkers in the exosome of endometrial cancer serum. Cancers (Basel). 2022;14(24):6262. https://doi.org/10.3390/cancers14246262.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J., Gong X., Yang L. et al. Loss of exosomal miR-26a-5p contributes to endometrial cancer lymphangiogenesis and lymphatic metastasis. Clin Transl Med. 2022;12(5):e846. https://doi.org/10.1002/ctm2.846.</mixed-citation><mixed-citation xml:lang="en">Wang J., Gong X., Yang L. et al. Loss of exosomal miR-26a-5p contributes to endometrial cancer lymphangiogenesis and lymphatic metastasis. Clin Transl Med. 2022;12(5):e846. https://doi.org/10.1002/ctm2.846.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Maida Y., Takakura M., Nishiuchi T. et al. Exosomal transfer of functional small RNAs mediates cancer-stroma communication in human endometrium. Cancer Med. 2016;5(2):304–14. https://doi.org/10.1002/cam4.545.</mixed-citation><mixed-citation xml:lang="en">Maida Y., Takakura M., Nishiuchi T. et al. Exosomal transfer of functional small RNAs mediates cancer-stroma communication in human endometrium. Cancer Med. 2016;5(2):304–14. https://doi.org/10.1002/cam4.545.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Gu X., Shi Y., Dong M. еt al. Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer. Cell Death Dis. 2021;12(9):818. https://doi.org/10.1038/s41419-021-04087-8.</mixed-citation><mixed-citation xml:lang="en">Gu X., Shi Y., Dong M. еt al. Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer. Cell Death Dis. 2021;12(9):818. https://doi.org/10.1038/s41419-021-04087-8.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Ding D.C., Chen W., Wang J.H., Lin S.Z. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan. Medicine (Baltimore). 2018;97(39):e12608. https://doi.org/10.1097/MD.0000000000012608.</mixed-citation><mixed-citation xml:lang="en">Ding D.C., Chen W., Wang J.H., Lin S.Z. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan. Medicine (Baltimore). 2018;97(39):e12608. https://doi.org/10.1097/MD.0000000000012608.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Che X., Jian F., Chen C. et al. PCOS serum-derived exosomal miR-27a-5p stimulates endometrial cancer cells migration and invasion. J Mol Endocrinol. 2020;64(1):1–12. https://doi.org/10.1530/JME-19-0159.</mixed-citation><mixed-citation xml:lang="en">Che X., Jian F., Chen C. et al. PCOS serum-derived exosomal miR-27a-5p stimulates endometrial cancer cells migration and invasion. J Mol Endocrinol. 2020;64(1):1–12. https://doi.org/10.1530/JME-19-0159.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao M., Mishra L., Deng C.X. The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111–23. https://doi.org/10.7150/ijbs.23230.</mixed-citation><mixed-citation xml:lang="en">Zhao M., Mishra L., Deng C.X. The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111–23. https://doi.org/10.7150/ijbs.23230.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao L., He Y., Peng F. et al. Endometrial cancer cells promote M2-like macrophage polarization by delivering exosomal miRNA-21 under hypoxia condition. J Immunol Res. 2020;2020:9731049. https://doi.org/10.1155/2020/9731049.</mixed-citation><mixed-citation xml:lang="en">Xiao L., He Y., Peng F. et al. Endometrial cancer cells promote M2-like macrophage polarization by delivering exosomal miRNA-21 under hypoxia condition. J Immunol Res. 2020;2020:9731049. https://doi.org/10.1155/2020/9731049.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Peres L.C., Cushing-Haugen K.L., Köbel M. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111(1):60–8. https://doi.org/10.1093/jnci/djy071.</mixed-citation><mixed-citation xml:lang="en">Peres L.C., Cushing-Haugen K.L., Köbel M. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111(1):60–8. https://doi.org/10.1093/jnci/djy071.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">McAlarnen L.A., Gupta P., Singh R. et al. Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies. Mol Ther Oncolytics. 2022;26:347–59. https://doi.org/10.1016/j.omto.2022.08.005.</mixed-citation><mixed-citation xml:lang="en">McAlarnen L.A., Gupta P., Singh R. et al. Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies. Mol Ther Oncolytics. 2022;26:347–59. https://doi.org/10.1016/j.omto.2022.08.005.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Li L., Zhang F., Zhang J. et al. Identifying serum small extracellular vesicle microRNA as a noninvasive diagnostic and prognostic biomarker for ovarian cancer. ACS Nano. 2023;17(19):19197–210. https://doi.org/10.1021/acsnano.3c05694.</mixed-citation><mixed-citation xml:lang="en">Li L., Zhang F., Zhang J. et al. Identifying serum small extracellular vesicle microRNA as a noninvasive diagnostic and prognostic biomarker for ovarian cancer. ACS Nano. 2023;17(19):19197–210. https://doi.org/10.1021/acsnano.3c05694.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Jo H., Park S. et al. Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer. Cancer Lett. 2022;542:215735. https://doi.org/10.1016/j.canlet.2022.215735.</mixed-citation><mixed-citation xml:lang="en">Wang W., Jo H., Park S. et al. Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer. Cancer Lett. 2022;542:215735. https://doi.org/10.1016/j.canlet.2022.215735.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Meng X., Müller V., Milde-Langosch K. et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7(13):16923–35. https://doi.org/10.18632/oncotarget.7850.</mixed-citation><mixed-citation xml:lang="en">Meng X., Müller V., Milde-Langosch K. et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7(13):16923–35. https://doi.org/10.18632/oncotarget.7850.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S., Choi M.C., Jeong J.Y. et al. Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. J Cancer. 2019;10(9):1958–67. https://doi.org/10.7150/jca.30231.</mixed-citation><mixed-citation xml:lang="en">Kim S., Choi M.C., Jeong J.Y. et al. Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. J Cancer. 2019;10(9):1958–67. https://doi.org/10.7150/jca.30231.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Su Y.Y., Sun L., Guo Z.R. et al. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer. J Ovarian Res. 2019;12(1):6. https://doi.org/10.1186/s13048-018-0477-x.</mixed-citation><mixed-citation xml:lang="en">Su Y.Y., Sun L., Guo Z.R. et al. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer. J Ovarian Res. 2019;12(1):6. https://doi.org/10.1186/s13048-018-0477-x.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Pan C., Stevic I., Müller V. et al. Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol. 2018;12(11):1935–48. https://doi.org/10.1002/1878-0261.12371.</mixed-citation><mixed-citation xml:lang="en">Pan C., Stevic I., Müller V. et al. Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol. 2018;12(11):1935–48. https://doi.org/10.1002/1878-0261.12371.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Xiong J., He X., Xu Y. et al. MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer. J Ovarian Res. 2021;14(1):74. https://doi.org/10.1186/s13048-021-00826-9.</mixed-citation><mixed-citation xml:lang="en">Xiong J., He X., Xu Y. et al. MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer. J Ovarian Res. 2021;14(1):74. https://doi.org/10.1186/s13048-021-00826-9.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Cappellesso R., Tinazzi A., Giurici T. et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014;122(9):685–93. https://doi.org/10.1002/cncy.21442.</mixed-citation><mixed-citation xml:lang="en">Cappellesso R., Tinazzi A., Giurici T. et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014;122(9):685–93. https://doi.org/10.1002/cncy.21442.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Cao J., Zhang Y., Mu J. et al. Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6. Hum Cell. 2021;34(4):1185–96. https://doi.org/10.1007/s13577-021-00522-2.</mixed-citation><mixed-citation xml:lang="en">Cao J., Zhang Y., Mu J. et al. Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6. Hum Cell. 2021;34(4):1185–96. https://doi.org/10.1007/s13577-021-00522-2.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Mitra A., Yoshida-Court K., Solley T.N. et al. Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells. Sci Rep. 2021;11(1):9149. https://doi.org/10.1038/s41598-021-88163-1.</mixed-citation><mixed-citation xml:lang="en">Mitra A., Yoshida-Court K., Solley T.N. et al. Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells. Sci Rep. 2021;11(1):9149. https://doi.org/10.1038/s41598-021-88163-1.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou J., Gong G., Tan H. et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 2015;33(6):2915–23. https://doi.org/10.3892/or.2015.3937.</mixed-citation><mixed-citation xml:lang="en">Zhou J., Gong G., Tan H. et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 2015;33(6):2915–23. https://doi.org/10.3892/or.2015.3937.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Ying X., Wu Q., Wu X. et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7(28):43076–87. https://doi.org/10.18632/oncotarget.9246.</mixed-citation><mixed-citation xml:lang="en">Ying X., Wu Q., Wu X. et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7(28):43076–87. https://doi.org/10.18632/oncotarget.9246.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Yunusova N., Dzhugashvili E., Yalovaya A. et al. Comparative analysis of tumor-associated microRNAs and tetraspanines from exosomes of plasma and ascitic fluids of ovarian cancer patients. Int J Mol Sci. 2022;24(1):464. https://doi.org/10.3390/ijms24010464.</mixed-citation><mixed-citation xml:lang="en">Yunusova N., Dzhugashvili E., Yalovaya A. et al. Comparative analysis of tumor-associated microRNAs and tetraspanines from exosomes of plasma and ascitic fluids of ovarian cancer patients. Int J Mol Sci. 2022;24(1):464. https://doi.org/10.3390/ijms24010464.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y., Xu L., Zheng J. et al. MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor. FEBS Open Bio. 2017;7(9):1258–66. https://doi.org/10.1002/2211-5463.12257.</mixed-citation><mixed-citation xml:lang="en">Xu Y., Xu L., Zheng J. et al. MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor. FEBS Open Bio. 2017;7(9):1258–66. https://doi.org/10.1002/2211-5463.12257.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Lai Y., Dong L., Jin H. et al. Exosome long non-coding RNA SOX2-OT contributes to ovarian cancer malignant progression by miR-181b-5p/SCD1 signaling. Aging (Albany NY). 2021;13(20):23726–38. https://doi.org/10.18632/aging.203645.</mixed-citation><mixed-citation xml:lang="en">Lai Y., Dong L., Jin H. et al. Exosome long non-coding RNA SOX2-OT contributes to ovarian cancer malignant progression by miR-181b-5p/SCD1 signaling. Aging (Albany NY). 2021;13(20):23726–38. https://doi.org/10.18632/aging.203645.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Ma R., Ye X., Cheng H. et al. Tumor-derived exosomal circRNA051239 promotes proliferation and migration of epithelial ovarian cancer. Am J Transl Res. 2021;13(3):1125–39.</mixed-citation><mixed-citation xml:lang="en">Ma R., Ye X., Cheng H. et al. Tumor-derived exosomal circRNA051239 promotes proliferation and migration of epithelial ovarian cancer. Am J Transl Res. 2021;13(3):1125–39.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamoto C.M., Oakes M.L., Murakami T. et al. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. J Ovarian Res. 2018;11(1):20. https://doi.org/10.1186/s13048-018-0391-2.</mixed-citation><mixed-citation xml:lang="en">Yamamoto C.M., Oakes M.L., Murakami T. et al. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. J Ovarian Res. 2018;11(1):20. https://doi.org/10.1186/s13048-018-0391-2.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Keserű J.S., Soltész B., Lukács J. et al. Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer. J Biotechnol. 2019;298:76–81. https://doi.org/10.1016/j.jbiotec.2019.04.015.</mixed-citation><mixed-citation xml:lang="en">Keserű J.S., Soltész B., Lukács J. et al. Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer. J Biotechnol. 2019;298:76–81. https://doi.org/10.1016/j.jbiotec.2019.04.015.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Szajnik M., Derbis M., Lach M. et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol Obstet (Sunnyvale). 2013;Suppl 4:3. https://doi.org/10.4172/2161-0932.S4-003.</mixed-citation><mixed-citation xml:lang="en">Szajnik M., Derbis M., Lach M. et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol Obstet (Sunnyvale). 2013;Suppl 4:3. https://doi.org/10.4172/2161-0932.S4-003.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Czystowska-Kuzmicz M., Sosnowska A., Nowis D. et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):3000. https://doi.org/10.1038/s41467-019-10979-3.</mixed-citation><mixed-citation xml:lang="en">Czystowska-Kuzmicz M., Sosnowska A., Nowis D. et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):3000. https://doi.org/10.1038/s41467-019-10979-3.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Lai H., Guo Y., Tian L. et al. Protein panel of serum-derived small extracellular vesicles for the screening and diagnosis of epithelial ovarian cancer. Cancers (Basel). 2022;14(15):3719. https://doi.org/10.3390/cancers14153719.</mixed-citation><mixed-citation xml:lang="en">Lai H., Guo Y., Tian L. et al. Protein panel of serum-derived small extracellular vesicles for the screening and diagnosis of epithelial ovarian cancer. Cancers (Basel). 2022;14(15):3719. https://doi.org/10.3390/cancers14153719.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Trinidad C.V., Pathak H.B., Cheng S. et al. Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer. Sci Rep. 2023;13(1):18341. https://doi.org/10.1038/s41598-023-44050-5.</mixed-citation><mixed-citation xml:lang="en">Trinidad C.V., Pathak H.B., Cheng S. et al. Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer. Sci Rep. 2023;13(1):18341. https://doi.org/10.1038/s41598-023-44050-5.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Yokoi A., Ukai M., Yasui T. et al. Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires. Sci Adv. 2023;9(27):eade6958. https://doi.org/10.1126/sciadv.ade6958.</mixed-citation><mixed-citation xml:lang="en">Yokoi A., Ukai M., Yasui T. et al. Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires. Sci Adv. 2023;9(27):eade6958. https://doi.org/10.1126/sciadv.ade6958.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang P., Zhou X., He M. et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat Biomed Eng. 2019;3(6):438–51. https://doi.org/10.1038/s41551-019-0356-9.</mixed-citation><mixed-citation xml:lang="en">Zhang P., Zhou X., He M. et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat Biomed Eng. 2019;3(6):438–51. https://doi.org/10.1038/s41551-019-0356-9.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Kong L., Xu F., Yao Y. et al. Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer. Front Oncol. 2023;13:1142755. https://doi.org/10.3389/fonc.2023.1142755.</mixed-citation><mixed-citation xml:lang="en">Kong L., Xu F., Yao Y. et al. Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer. Front Oncol. 2023;13:1142755. https://doi.org/10.3389/fonc.2023.1142755.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta P., Kadamberi I.P., Mittal S. et al. Tumor derived extracellular vesicles drive T cell exhaustion in tumor microenvironment through sphingosine mediated signaling and impacting immunotherapy outcomes in ovarian cancer. Adv Sci (Weinh). 2022;9(14):e2104452. https://doi.org/10.1002/advs.202104452.</mixed-citation><mixed-citation xml:lang="en">Gupta P., Kadamberi I.P., Mittal S. et al. Tumor derived extracellular vesicles drive T cell exhaustion in tumor microenvironment through sphingosine mediated signaling and impacting immunotherapy outcomes in ovarian cancer. Adv Sci (Weinh). 2022;9(14):e2104452. https://doi.org/10.1002/advs.202104452.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Li N., Lin G., Zhang Y. et al. Exosome-related protein CRABP2 is upregulated in ovarian carcinoma and enhances cell proliferation. Discov Oncol. 2022;13(1):33. https://doi.org/10.1007/s12672-022-00492-3.</mixed-citation><mixed-citation xml:lang="en">Li N., Lin G., Zhang Y. et al. Exosome-related protein CRABP2 is upregulated in ovarian carcinoma and enhances cell proliferation. Discov Oncol. 2022;13(1):33. https://doi.org/10.1007/s12672-022-00492-3.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Dorayappan K.D.P, Gardner M.L., Hisey C.L. et al. A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer. Cancer Res. 2019;79(13):3503–13. https://doi.org/10.1158/0008-5472.CAN-18-3538.</mixed-citation><mixed-citation xml:lang="en">Dorayappan K.D.P, Gardner M.L., Hisey C.L. et al. A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer. Cancer Res. 2019;79(13):3503–13. https://doi.org/10.1158/0008-5472.CAN-18-3538.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Vaksman O., Tropé C., Davidson B., Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35(9):2113–20. https://doi.org/10.1093/carcin/bgu130.</mixed-citation><mixed-citation xml:lang="en">Vaksman O., Tropé C., Davidson B., Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35(9):2113–20. https://doi.org/10.1093/carcin/bgu130.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Filippov-Levy N., Cohen-Schussheim H., Tropé C.G. et al. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. Gynecol Oncol. 2018;148(3):559–66. https://doi.org/10.1016/j.ygyno.2018.01.004.</mixed-citation><mixed-citation xml:lang="en">Filippov-Levy N., Cohen-Schussheim H., Tropé C.G. et al. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. Gynecol Oncol. 2018;148(3):559–66. https://doi.org/10.1016/j.ygyno.2018.01.004.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Qiu J.J., Lin X.J., Tang X.Y. et al. Exosomal metastasis-associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int J Biol Sci. 2018;14(14):1960–73. https://doi.org/10.7150/ijbs.28048.</mixed-citation><mixed-citation xml:lang="en">Qiu J.J., Lin X.J., Tang X.Y. et al. Exosomal metastasis-associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int J Biol Sci. 2018;14(14):1960–73. https://doi.org/10.7150/ijbs.28048.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Asare-Werehene M., Hunter R.A., Gerber E. et al. The application of an extracellular vesicle-based biosensor in early diagnosis and prediction of chemoresponsiveness in ovarian cancer. Cancers (Basel). 2023;15(9):2566. https://doi.org/10.3390/cancers15092566.</mixed-citation><mixed-citation xml:lang="en">Asare-Werehene M., Hunter R.A., Gerber E. et al. The application of an extracellular vesicle-based biosensor in early diagnosis and prediction of chemoresponsiveness in ovarian cancer. Cancers (Basel). 2023;15(9):2566. https://doi.org/10.3390/cancers15092566.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Gerber E., Asare-Werehene M., Reunov A. et al. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin. J Ovarian Res. 2023;16(1):14. https://doi.org/10.1186/s13048-022-01086-x.</mixed-citation><mixed-citation xml:lang="en">Gerber E., Asare-Werehene M., Reunov A. et al. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin. J Ovarian Res. 2023;16(1):14. https://doi.org/10.1186/s13048-022-01086-x.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Li W., Lu Y., Yu X. et al. Detection of exosomal tyrosine receptor kinase B as a potential biomarker in ovarian cancer. J Cell Biochem. 2019;120(4):6361–9. https://doi.org/10.1002/jcb.27923.</mixed-citation><mixed-citation xml:lang="en">Li W., Lu Y., Yu X. et al. Detection of exosomal tyrosine receptor kinase B as a potential biomarker in ovarian cancer. J Cell Biochem. 2019;120(4):6361–9. https://doi.org/10.1002/jcb.27923.</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Yokoi A., Yoshioka Y., Hirakawa A. et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8(52):89811–23. https://doi.org/10.18632/oncotarget.20688.</mixed-citation><mixed-citation xml:lang="en">Yokoi A., Yoshioka Y., Hirakawa A. et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8(52):89811–23. https://doi.org/10.18632/oncotarget.20688.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Jo A., Green A., Medina J.E. et al. High-throughput profiling of extracellular vesicles for earlier ovarian cancer detection. Adv Sci (Weinh). 2023;10(27):e2301930. https://doi.org/10.1002/advs.202301930.</mixed-citation><mixed-citation xml:lang="en">Jo A., Green A., Medina J.E. et al. High-throughput profiling of extracellular vesicles for earlier ovarian cancer detection. Adv Sci (Weinh). 2023;10(27):e2301930. https://doi.org/10.1002/advs.202301930.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshimura A., Sawada K., Nakamura K. et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065. https://doi.org/10.1186/s12885-018-4974-5.</mixed-citation><mixed-citation xml:lang="en">Yoshimura A., Sawada K., Nakamura K. et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065. https://doi.org/10.1186/s12885-018-4974-5.</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi M., Sawada K., Nakamura K. et al. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. J Ovarian Res. 2018;11(1):81. https://doi.org/10.1186/s13048-018-0458-0.</mixed-citation><mixed-citation xml:lang="en">Kobayashi M., Sawada K., Nakamura K. et al. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. J Ovarian Res. 2018;11(1):81. https://doi.org/10.1186/s13048-018-0458-0.</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Au Yeung C.L., Co N.N., Tsuruga T. et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150. https://doi.org/10.1038/ncomms11150.</mixed-citation><mixed-citation xml:lang="en">Au Yeung C.L., Co N.N., Tsuruga T. et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150. https://doi.org/10.1038/ncomms11150.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Wang C., Wang J., Shen X. et al. LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1. J Exp Clin Cancer Res. 2021;40(1):101. https://doi.org/10.1186/s13046-021-01899-6.</mixed-citation><mixed-citation xml:lang="en">Wang C., Wang J., Shen X. et al. LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1. J Exp Clin Cancer Res. 2021;40(1):101. https://doi.org/10.1186/s13046-021-01899-6.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng L., Zhang K., Qing Y. et al. Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells. J Ovarian Res. 2020;13(1):9. https://doi.org/10.1186/s13048-020-0609-y.</mixed-citation><mixed-citation xml:lang="en">Cheng L., Zhang K., Qing Y. et al. Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells. J Ovarian Res. 2020;13(1):9. https://doi.org/10.1186/s13048-020-0609-y.</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Černe K., Kelhar N., Resnik N. et al. Characteristics of extracellular vesicles from a high-grade serous ovarian cancer cell line derived from a platinum-resistant patient as a potential tool for aiding the prediction of responses to chemotherapy. Pharmaceuticals (Basel). 2023;16(6):907. https://doi.org/10.3390/ph16060907.</mixed-citation><mixed-citation xml:lang="en">Černe K., Kelhar N., Resnik N. et al. Characteristics of extracellular vesicles from a high-grade serous ovarian cancer cell line derived from a platinum-resistant patient as a potential tool for aiding the prediction of responses to chemotherapy. Pharmaceuticals (Basel). 2023;16(6):907. https://doi.org/10.3390/ph16060907.</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Q., Fang X., Chen Y. et al. Exosomal lncRNA UCA1 from cancer-associated fibroblasts enhances chemoresistance in vulvar squamous cell carcinoma cells. J Obstet Gynaecol Res. 2021;47(1):73–87. https://doi.org/10.1111/jog.14418.</mixed-citation><mixed-citation xml:lang="en">Gao Q., Fang X., Chen Y. et al. Exosomal lncRNA UCA1 from cancer-associated fibroblasts enhances chemoresistance in vulvar squamous cell carcinoma cells. J Obstet Gynaecol Res. 2021;47(1):73–87. https://doi.org/10.1111/jog.14418.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
